About Applied Immune Technologies
Applied Immune Technologies is a company based in Haifa (Israel) founded in 2006 was acquired by Adicet Bio in January 2016. Applied Immune Technologies has raised $4 million across 2 funding rounds from investors including Adicet Bio and Pontifax Venture Capital. Applied Immune Technologies operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Haifa, Israel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4 M (USD)
in 2 rounds
-
Latest Funding Round
$600 K (USD), Grant
Jan 01, 2011
-
Investors
Adicet Bio
& 1 more
-
Employee Count
Not available
-
Acquired by
Adicet Bio
(Jan 27, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Applied Immune Technologies
Applied Immune Technologies has successfully raised a total of $4M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $600 thousand completed in January 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Applied Immune Technologies
Applied Immune Technologies has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Adicet Bio and Pontifax Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Immune cell therapies for cancer treatment are developed.
|
Locked | Locked | Locked |
Investor details for Applied Immune Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Applied Immune Technologies
Investment portfolio details for Applied Immune Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Applied Immune Technologies
Detailed financials for Applied Immune Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Applied Immune Technologies Comparisons
Peer comparison for Applied Immune Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Applied Immune Technologies
Applied Immune Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Applied Immune Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Applied Immune Technologies
Complete news archive for Applied Immune Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Applied Immune Technologies
Applied Immune Technologies was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Applied Immune Technologies is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Applied Immune Technologies is a funded company, having raised a total of $4M across 2 funding rounds to date.
Applied Immune Technologies was founded in 2006 in Haifa, Israel, within the biotechnology sector. Therapeutic molecules are developed for cancer, viral, and autoimmune diseases. T-Cell Receptor-Like (TCRL) antibodies, targeted at intracellular-derived peptides, are created for therapeutic and diagnostic uses. These include pathology diagnostics, vaccine design, validation, monitoring, and antigen presentation analysis in disease states. Technology for discovering TCRL targets is also applied.
Applied Immune Technologies's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Applied Immune Technologies has 2 investors. Key investors include Adicet Bio, and Pontifax Venture Capital.